Maxcyte Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Maxcyte Inc 's ROA in the second quarter of 2026?
Maxcyte Inc recorded a cumulative net loss of $-36 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -17.93%.

However, within the Healthcare sector 348 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3430, from total ROA ranking in the first quarter of 2026 at 4074.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-16.05 %	-15.43 %	-12.4 %	-11.3 %	-9.14 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-36	-39	-45	-46	-45
Return On Assets (TTM)	-17.93 %	-18.85 %	-20.62 %	-20.41 %	-19.43 %
MXCT's Total Ranking	# 3430	# 4074	# 3550	# 3562	# 3556
Total Assets (TTM) in million	184	194	203	213	220
Seq. Total Assets Change	-5.14 %	-3.97 %	-5.14 %	-2.86 %	-4.44 %
Seq. Net Income Change	-	-	-	-	-

MXCT's 5 Years Annual ROA >> Back to MXCT Management Effectiveness >> Compare MXCT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 21
Sector	# 349
Overall	# 3386

Return On Assets Statistics
High	Average	Low
-6.78 %	-13.81 %	-20.62 %
(Mar 31 2022)		(Dec 31 2025)

News about Maxcyte inc Return on Assets ROA

MaxCyte at 25: Navigating Innovation and Financial Challenges in the Quest for Genetic Cures,

IntroductionMaxCyte Inc. proudly commemorates 25 years of innovation in the field of cell engineering, a milestone marked by numerous advancements in cell and gene therapy since its inception in 1999. Despite its celebrated history, the company faces challenges, including a significant net loss reported for the second quarter of 2024. However, its recent strategic partnership with Kamau Therapeutics presents an optimistic outlook for the future.Celebrating Two Decades of InnovationSince 1999, MaxCyte has been at the forefront of non-viral cell engineering, enabling groundbreaking projects in cell and gene therapy. The company’s technological achievements, particularly its Flow Electroporation technology and ExPERT platform, have laid the foundational framework for numerous therapeutic developments. These innovations have played a crucial role in advancing the efficiency and effectiveness of cell engineering, positioning MaxCyte as a leader in the biotech sector.

Financial Statements
Maxcyte Inc 's Assets	$ 184 million	MXCT's Balance sheet
Maxcyte Inc 's Income	$ -9 million	Quarterly MXCT's Income Statement
MXCT's Income by Division		See MXCT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	10.34 %	-10.62 %	-6.96 %	-0.76 %	-
Total Assets in million	255	231	259	278	280
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-45	-41	-38	-24	-19
Annual Return On Assets	-17.5 %	-17.76 %	-14.66 %	-8.48 %	-6.81 %

MXCT's 5 Years Annual ROA >> Back to MXCT Management Effectiveness >> Compare MXCT ROA to its Competitors

More Return On Assets Ratios
MXCT's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MXCT's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MXCT's Competitors
Subscribers only: Roa for Maxcyte Inc 's Suppliers
Subscribers only: Return On Assets for MXCT's Customers

You may also want to know
MXCT's Roi	MXCT's Inventory Turnover Ratio	MXCT's Growth Rates	MXCT's Dividend Comparisons
	MXCT's Profitability Ratios	MXCT's Asset Turnover Ratio	MXCT's Dividend Growth
MXCT's Roe	MXCT's Valuation Ratios	MXCT's Financial Strength Ratios	MXCT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-03T12:02:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.